View our webcast presentation at the LD Micro Invitational XIV today at 1 PM ET. Access it here: bit.ly/3vDON0X

$CNSP #GlioblastomaMultiforme #GBM #Oncology

We are pleased to be presenting at the LD Micro Invitational XIV on Tuesday, April 9 at 1 PM ET. Hope to see you all there!

bit.ly/3vDON0X

$CNSP #GlioblastomaMultiforme #GBM #Oncology

We are looking forward to presenting at the MedInvest Biotech & Pharma Investor Conference happening April 3-4 in New York City! Hope to see you there.

$CNSP #GlioblastomaMultiforme #GBM #Oncology

April is #CancerControlMonth . The common goal of this month is to bring awareness the importance of improving cancer treatments and increasing the survival rate of cancer. Learn more here: bit.ly/3wYRIkZ ​

$CNSP #GlioblastomaMultiforme #GBM #Oncology

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements

bit.ly/43JnajD
$CNSP #GBM #GlioblastomaMultiforme #Oncology

CNS Pharmaceuticals to Present at Two Investor Conferences in April

bit.ly/43EETZE
$CNSP #GBM #Glioblastoma #Glioblastoma Multiforme

Learn more about #Glioblastoma and what we are doing to potentially address it here: bit.ly/49e90cb

$CNSP #Glioblastoma Multiforme #GBM #Oncology

#GBMStat Despite first being identified in the scientific literature in the 1920’s, there have only been four drugs and one device ever approved by the FDA specifically for the treatment of #glioblastoma .

$CNSP #GlioblastomaMultiforme #Oncology

#DidYouKnow The five-year survival rate for #glioblastoma patients is only 6.9%, and the average length of survival for glioblastoma patients is estimated to be only 8 months.

bit.ly/3ZWWubF
$CNSP #GlioblastomaMultiforme #GBM #Oncology

#DidYouKnow : #GBM accounts for 50.1 percent of all primary malignant brain tumors.

$CNSP #GlioblastomaMultiforme #GBM #Oncology

Our lead product candidate is currently in development for the treatment of #glioblastomamultiforme ( #GBM ), an aggressive and incurable form of brain cancer.

bit.ly/3npZn3X $CNSP

CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system malignancies.

$CNSP #GlioblastomaMultiforme #GBM #Oncology

Want to follow our progress? Sign up for email alerts here: bit.ly/3qrwDZk

$CNSP #GlioblastomaMultiforme #GBM #Oncology

Our lead product candidate is an innovative first in its class anthracycline to appear to cross over the blood brain barrier and kill tumor cells as a potential treatment option for #glioblastoma . bit.ly/3ZWWubF

$CNSP #GlioblastomaMultiforme #GBM #Oncology

Our lead product candidate is an innovative first in its class anthracycline to appear to cross over the blood brain barrier and kill tumor cells as a potential treatment option for #glioblastoma .

bit.ly/3ZWWubF
$CNSP #GlioblastomaMultiforme #GBM #Oncology

#TuneIn at 11 AM ET today for our CEO’s appearance on Benzinga Live Access. Watch John Climaco discuss all things $CNSP here: bit.ly/42ODoYh

#GlioblastomaMultiforme #GBM #Oncology

#InCaseYouMissedIt : We recently achieved completion of planned enrollment in our potentially pivotal study of Berubicin for the treatment of #GlioblastomaMultiforme

bit.ly/3O8x1ZQ
$CNSP #GBM #Oncology

Want to follow our progress? Sign up for email alerts here: bit.ly/3qrwDZk

$CNSP #GlioblastomaMultiforme #GBM #Oncology

Watch this video on how our lead product candidate, Berubicin is designed to work: bit.ly/3ZWWubF

$CNSP #Glioblastoma Multiforme #GBM #Oncology #Glioblastoma

CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering

bit.ly/3Omy0Wv
$CNSP #GlioblastomaMultiforme #GBM #Oncology